Enormous progress has been made in the last half-century in the management of diseases
closely integrated with excess body weight, such as hypertension, adult-onset diabetes and …

Leptin, a hormone that is capable of effectively reducing food intake and body weight, was
initially considered for use in the treatment of obesity. However, obese subjects have since …

The discovery of leptin changed the view of adipose tissue from that of a passive vessel that
stores fat to that of a dynamic endocrine organ that actively regulates behaviour and …

Background Glucagon-like peptide-1 receptor (GLP-1R) agonists are approved for the
treatment of type 2 diabetes and obesity and elicit robust improvements in glycemic control …

Currently, there is no disease-modifying treatment available for Alzheimer's and Parkinson's
disease (AD and PD) and that includes the highly controversial approval of the Aβ-targeting …

In the last two decades we have witnessed sizable progress in defining the role of
gastrointestinal signals in the control of glucose and energy homeostasis. Specifically, the …

We report the discovery of a new monomeric peptide that reduces body weight and diabetic
complications in rodent models of obesity by acting as an agonist at three key metabolically …

Obesity and its comorbidities, including type 2 diabetes mellitus, cardiovascular disease,
heart failure and non-alcoholic liver disease are a major health and economic burden with …

The incretin hormone glucagon-like peptide-1 (GLP-1) has received enormous attention
during the past three decades as a therapeutic target for the treatment of obesity and type 2 …

Because human energy metabolism evolved to favor adiposity over leanness, the
availability of palatable, easily attainable, and calorically dense foods has led to …